+143.6%
VLO vs MRNA
+511.3%
-367.7%
-12.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | -2.2% | +2.2% | 0.0% |
| 7D | +5.2% | +5.5% | -0.3% | +5.3% |
| 30D | +22.6% | +158.7% | -136.1% | +25.0% |
| 3M | +43.8% | +182.1% | -138.4% | +46.2% |
| 6M | +65.7% | +151.8% | -86.1% | +69.5% |
| YTD | +131.1% | +393.6% | -262.5% | +129.7% |
| 1Y | +143.6% | +499.5% | -355.8% | +141.6% |
| All | +143.6% | +511.3% | -367.7% | +141.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling